ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

plecanatide

Also written as “Plecanatide”, “SP-304 0.3 mg” and “SP-304 1.0 mg”.

Its studies are mostly in Constipation · Irritable Bowel Syndrome · Bronchiolitis Obliterans Syndrome, led by 2 companies.

Drug pagePlecanatide: every studyAll 14 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 6, 201113 company-led studies, 1 open or runningNext primary completion: Oct 18, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bausch Health Companies121 open or runningphase 3since Sep 6, 2011Jan 12, 2010Oct 18, 2027phase 2 · NCT07723924
Shandong Luoxin Pharmaceutical Group Stockits history only10 open or runningphase 3since Nov 4, 2021Nov 4, 2021none ahead

Also a collaborator on its studies: Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bausch Health Companies only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 12, 2010First study: phase 2 study in ConstipationFirst studyNCT01053962 · 84 enrolled · United States
  2. Sep 6, 2011Phase 3 study in ConstipationNCT01429987 · 951 enrolled · United States
  3. Nov 2, 2012Phase 2 study in Irritable Bowel Syndrome Characterized by ConstipationNCT01722318 · 428 enrolled · United States
  4. Aug 7, 2013Phase 3 study in Bronchiolitis Obliterans SyndromeNCT01919697 · 2,370 enrolled · United States, Canada
  5. Nov 5, 2013Phase 3 study in ConstipationNCT01982240 · 1,394 enrolled · United States, Canada
  6. Apr 22, 2014Phase 3 study in ConstipationNCT02122471 · 1,410 enrolled · United States
  7. Jan 20, 2015Phase 3 study in Irritable Bowel Syndrome Characterized by ConstipationNCT02387359 · 1,054 enrolled · United States
  8. Jun 23, 2015Phase 3 study in Irritable Bowel Syndrome Characterized by ConstipationNCT02493452 · 1,135 enrolled · United States
  9. Feb 29, 2016Phase 3 study in Irritable Bowel SyndromeNCT02706483 · 2,272 enrolled · United States
  10. Apr 18, 2017Phase 2 study in Chronic Idiopathic ConstipationNCT03120520 · 124 enrolled · United States
  11. Jul 12, 2018Phase 2 study in Irritable Bowel Syndrome With ConstipationNCT03596905 · 218 enrolled · United States
  12. Jul 20, 2026Phase 2 study in ConstipationNCT07723924 · 180 enrolled · United States

Ahead

  1. Oct 18, 2027Primary completion: phase 2 study in ConstipationNCT07723924

TargetBeta

GUCY2C →read by rule
“An agonist of intestinal guanylate cyclase type C (GC-C) which is almost structurally identical to human uroguanylin, with laxative and anti-nociceptive activities”NCIt, by rule
“Heat-stable enterotoxin receptor agonist”ChEMBL 37, by rule

Studies

All 12 Bausch Health Companies leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07723924Constipation · United States2Active, not recruitingOct 18, 2027180
NCT03596905Irritable Bowel Syndrome With Constipation · United States2CompletedNov 25, 2024218
NCT03120520Chronic Idiopathic Constipation · United States2CompletedSep 7, 2018124
NCT02706483Irritable Bowel Syndrome · United States3CompletedMay 20172,272
NCT02493452Irritable Bowel Syndrome Characterized by Constipation · United States3CompletedNov 20161,135
NCT02387359Irritable Bowel Syndrome Characterized by Constipation · United States3CompletedDec 20161,054
NCT02122471Constipation · United States3CompletedMay 20151,410
NCT01982240Constipation · United States, Canada3CompletedApr 20151,394
NCT01919697Bronchiolitis Obliterans Syndrome · United States, Canada3CompletedJan 20162,370
NCT01722318Irritable Bowel Syndrome Characterized by Constipation · United States2CompletedApr 2014428
NCT01429987Constipation · United States3CompletedDec 2012951
NCT01053962Constipation · United States2CompletedAug 201084

How it is read

Names in the registry

  • “Plecanatide”, 10 entries
  • “plecanatide”, 2 entries
  • “SP-304 0.3 mg”, 1 entry
  • “SP-304 1.0 mg”, 1 entry
  • “SP-304 3.0 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.